Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
Sormani MP, Schiavetti I, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Brescia Morra V, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Furlan R, Salvetti M; MuSC-19 Study Group. Sormani MP, et al. Among authors: patti f. Mult Scler. 2022 Jun;28(7):1034-1040. doi: 10.1177/13524585211035318. Epub 2021 Jul 30. Mult Scler. 2022. PMID: 34328824
Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study.
Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V, Milani N, Milanese C, Moiola L, Patti F, Pilato V, Pozzilli C, Trojano M, Zaffaroni M, Comi G; Immunomodulatory Treatment of Early onset MS Group. Ghezzi A, et al. Among authors: patti f. Mult Scler. 2005 Aug;11(4):420-4. doi: 10.1191/1352458505ms1206oa. Mult Scler. 2005. PMID: 16042224 Clinical Trial.
Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group. Patti F, et al. Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544. Mult Scler. 2009. PMID: 19542262
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group. Trojano M, et al. Among authors: patti f. Ann Neurol. 2009 Oct;66(4):513-20. doi: 10.1002/ana.21757. Ann Neurol. 2009. PMID: 19847899
Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group. Patti F, et al. Mult Scler. 2010 Jan;16(1):68-77. doi: 10.1177/1352458509350309. Epub 2009 Dec 7. Mult Scler. 2010. PMID: 19995846 Clinical Trial.
Multiple sclerosis in Italy: cost-of-illness study.
Patti F, Amato MP, Trojano M, Solaro C, Pappalardo A, Zipoli V, Portaccio E, Paolicelli D, Paolillo A, Mennini FS, Marcellusi A, Ricci C, Battaglia MA. Patti F, et al. Neurol Sci. 2011 Oct;32(5):787-94. doi: 10.1007/s10072-011-0499-2. Epub 2011 Mar 16. Neurol Sci. 2011. PMID: 21409509
596 results